This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

This study has been completed.
Information provided by:
Astellas Pharma Inc Identifier:
First received: August 24, 2006
Last updated: April 9, 2008
Last verified: April 2008
To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid

Condition Intervention Phase
Urinary Bladder, Overactive Drug: solifenacin succinate Drug: tolterodine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Paralleled, Active Controlled, Multi-Center Study of the Efficacy and Safety of 5mg Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Change from baseline in mean number of micturitions per 24 hours [ Time Frame: 8 Weeks ]

Secondary Outcome Measures:
  • Change from baseline in mean volume voided per micturition [ Time Frame: 8 Weeks ]
  • Change from baseline in mean number of incontinence episodes per 24 hours [ Time Frame: 8 Weeks ]
  • Change from baseline in mean urgency frequency per 24 hours [ Time Frame: 8 Weeks ]
  • Change from baseline in mean nocturia episodes per 24 hours [ Time Frame: 8 Weeks ]

Enrollment: 246
Study Start Date: September 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: solifenacin succinate
Other Names:
  • Vesicare
  • YM905
Active Comparator: 2 Drug: tolterodine


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients willing and able to complete the micturition diary correctly
  • Patients experiencing frequency of micturition as verified in the diary
  • Patients experiencing significant post void residual volume
  • OAB symptoms including urinary frequency, urgency or urge incontinence for 3 months or more.

Exclusion Criteria:

  • Significant post void residual volume
  • Patients with indwelling catheters or practicing intermittent self- catheterization
  • Known or suspected hypersensitivity to solifenacin succinate or other anticholinergics or lactose
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00368706

Beijing, China, 100000
Chong Qing, China, 404000
Hang Zhou, China, 310000
Shanghai, China, 200000
Sponsors and Collaborators
Astellas Pharma Inc
Principal Investigator: Use Central Contact Peking University First Hospital
  More Information

Responsible Party: Director, Astellas Pharma Inc. Identifier: NCT00368706     History of Changes
Other Study ID Numbers: 90506/CHoTD01
Study First Received: August 24, 2006
Last Updated: April 9, 2008

Keywords provided by Astellas Pharma Inc:
Overactive bladder
Urinary incontinence
Treatment outcomes

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Solifenacin Succinate
Tolterodine Tartrate
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on June 23, 2017